DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues by Craig, Justin M. et al.
 
DNA Fragmentation Simulation Method (FSM) and Fragment Size
Matching Improve aCGH Performance of FFPE Tissues
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Craig, Justin M., Natalie Vena, Shakti Ramkissoon, Ahmed
Idbaih, Shaun D. Fouse, Memet Ozek, Aydin Sav, D. Ashley Hill,
Linda R. Margraf, Charles G. Eberhart, Mark W. Kieran, Andrew
D. Norden, Patrick Y. Wen, Massimo Loda, Sandro Santagata,
Keith L. Ligon, and Azra H. Ligon. 2012. DNA fragmentation
simulation method (FSM) and fragment size matching improve
aCGH performance of FFPE tissues. PLoS ONE 7(6): e38881.
Published Version doi:10.1371/journal.pone.0038881
Accessed February 19, 2015 10:45:33 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10436306
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAADNA Fragmentation Simulation Method (FSM) and
Fragment Size Matching Improve aCGH Performance of
FFPE Tissues
Justin M. Craig
1,2,3, Natalie Vena
1,2,3, Shakti Ramkissoon
1,3,4, Ahmed Idbaih
5, Shaun D. Fouse
6,
Memet Ozek
7, Aydin Sav
8, D. Ashley Hill
9, Linda R. Margraf
10, Charles G. Eberhart
11,
Mark W. Kieran
12,13,17, Andrew D. Norden
14,15,17, Patrick Y. Wen
14,15,17, Massimo Loda
2,4,17,
Sandro Santagata
4,16,17, Keith L. Ligon
1,2,3,4,16,17*, Azra H. Ligon
1,2,3,4,17*
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, 2Center for Molecular Oncologic Pathology, Dana-
Farber Cancer Institute, Boston, Massachusetts, United States of America, 3Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, 4Department
of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 5Hopital Pitie Salpetriere, Service de Neurologie Mazarin, Paris, France,
6Department of Neurosurgery, Brain Tumor Research Center, University of California San Francisco, San Francisco, California, United States of America, 7Division of
Pediatric Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey, 8Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey,
9Department of Pathology, Children’s National Medical Center, Washington, District of Columbia, United States of America, 10Department of Pathology, The University
of Texas Southwestern Medical Center, Children’s Medical Center, Dallas, Texas, United States of America, 11Departments of Pathology, Oncology and Ophthalmology,
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 12Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston,
Massachusetts, United States of America, 13Department of Pediatrics, Boston Children’s Hospital, Boston, Massachusetts, United States of America, 14Department of
Neurology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 15Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston,
Massachusetts, United States of America, 16Department of Pathology, Boston Children’s Hospital, Boston, Massachusetts, United States of America, 17Harvard Medical
School, Boston, Massachusetts, United States of America
Abstract
Whole-genome copy number analysis platforms, such as array comparative genomic hybridization (aCGH) and single
nucleotide polymorphism (SNP) arrays, are transformative research discovery tools. In cancer, the identification of genomic
aberrations with these approaches has generated important diagnostic and prognostic markers, and critical therapeutic
targets. While robust for basic research studies, reliable whole-genome copy number analysis has been unsuccessful in
routine clinical practice due to a number of technical limitations. Most important, aCGH results have been suboptimal
because of the poor integrity of DNA derived from formalin-fixed paraffin-embedded (FFPE) tissues. Using self-
hybridizations of a single DNA sample we observed that aCGH performance is significantly improved by accurate DNA size
determination and the matching of test and reference DNA samples so that both possess similar fragment sizes. Based on
this observation, we developed a novel DNA fragmentation simulation method (FSM) that allows customized tailoring of the
fragment sizes of test and reference samples, thereby lowering array failure rates. To validate our methods, we combined
FSM with Universal Linkage System (ULS) labeling to study a cohort of 200 tumor samples using Agilent 1 M feature arrays.
Results from FFPE samples were equivalent to results from fresh samples and those available through the glioblastoma
Cancer Genome Atlas (TCGA). This study demonstrates that rigorous control of DNA fragment size improves aCGH
performance. This methodological advance will permit the routine analysis of FFPE tumor samples for clinical trials and in
daily clinical practice.
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Introduction
Tumor-specific genomic aberrations are of great diagnostic and
prognostic value. In addition, these aberrations are increasingly
useful in selecting targeted therapies for individual patients [1].
Current assays to establish copy number changes in clinical
oncology are based on fluorescence in situ hybridization (FISH)
and polymerase chain reaction (PCR) strategies designed to detect
individual genomic alterations. However, large-scale cancer
genome analyses continue to uncover specific aberrations in
multiple cancers, and this, in turn, has driven the need for
multiplex copy number testing in cancer research and clinical
practice [2–4]. Genome-wide technologies to determine copy
number changes such as array comparative genomic hybridization
(aCGH) and single nucleotide polymorphism (SNP) arrays were
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38881among the first whole-genome technologies developed [5]. More
recently, these technologies have been able to query the genome at
intra-exon resolution and, as demonstrated in recent large-scale
projects such as The Cancer Genome Atlas [4], can offer not only
high-throughput analysis but also robust genome-wide copy
number data.
Copy number analysis assays have been widely used in the
research setting. Most of these basic research studies use frozen
tumor samples that yield high-quality, intact DNA. The applica-
tion of similar assays in clinical trials and in the routine clinical
diagnosis of tumors has been unexpectedly slow, however. The
greatest impediment to clinical implementation has been the
technical challenges encountered during the processing and
analysis of formalin-fixed paraffin-embedded (FFPE) samples, the
mainstay of pathology department workflow. The inconsistent
aCGH data that often results from FFPE samples is generally
attributed to reduced DNA integrity. The relatively poor quality
and variable results obtained from FFPE aCGH are particularly
concerning because aCGH requires significantly more tissue than
FISH or colorimetric in situ hybridization (CISH), both of which
are performed routinely using FFPE specimens.
Early attempts at aCGH analysis of FFPE specimens were
hindered because of inadequate sensitivity and specificity [6,7].
Improvements in DNA extraction protocols [8–11], labeling
techniques [12], and aCGH platforms [5,13,14] subsequently
facilitated the analysis of FFPE samples in the research setting. To
date, several studies have suggested that informative aCGH data
can be generated from FFPE tissues [8,9,15–21], although our
own prior experience and several reports in the literature indicate
that one-third of FFPE specimens generate suboptimal aCGH
results using standard methods [9]. This is particularly relevant for
older specimens such as those used in retrospective analysis (e.g.,
clinical trials cohorts) [7,15,16,19,22].
Although the compromised integrity of DNA extracted from
FFPE tissues has long been suspected as the source of the technical
difficulties with FFPE aCGH, direct demonstration of this causal
relationship and how to remedy it has proven challenging [7].
Several quality control (QC) metrics have been proposed for
prospectively determining DNA suitability for aCGH. For each of
these methods DNA degradation has generally been assessed using
measurements of DNA size. Examples include: (1) multiplex-PCR
to exclude DNA samples that fail to produce minimum size
lengths; (2) gel electrophoresis to exclude DNA samples with
average fragment size below a given minimum molecular weight;
and (3) whole genome amplification (WGA) to exclude DNA
samples that result in low DNA yields [9,16,21,23,24]. It is
important to note that these studies assess DNA integrity prior to
DNA labeling and subsequent hybridization. The specific condi-
tions involved in DNA labeling - whether enzymatic- or chemical-
based - cause additional fragmentation and physical modification
of DNA [24,25]. Therefore, any quality assessments performed
prior to these steps do not evaluate the integrity of the DNA that is
actually being hybridized to the array. Furthermore, these metrics
help prevent assay failure without offering methods for improving
the performance of samples known to contain suboptimal DNA.
If aCGH of FFPE specimens is to become feasible clinically, the
process must be standardized to eliminate sample-to-sample
variability as well as to significantly enhance both data quality
and reproducibility [26,27]. In this study, we examine the effect of
DNA fragmentation on the outcome of aCGH analysis and
describe a novel and powerful method designed to generate robust
data and eliminate unpredictable quality variation among samples.
Utilizing this method, we obtain significantly enhanced aCGH
performance from both fresh and fixed sources of DNA. As proof
of the versatility of our approach, we performed a rigorous
demonstration on Agilent 1 M oligonucleotide arrays using a
variety of FFPE glioma specimens of varying block age (1–15 yrs).
Results
Array Performance is Improved When Test and Reference
DNA Samples Possess Similar Fragment Sizes
We first determined the effects of DNA fragment size on aCGH
data quality. To do this, we conducted a series of self-
hybridizations using a commercially available, high-quality geno-
mic DNA (gDNA) sample that is a common reference standard in
Agilent aCGH analyses (Promega, G1471, Madison, WI). The
reference gDNA had a high molecular weight distribution at the
outset (mode fragment length .10 kb). The sample was split into
eight identical aliquots and heat-fragmented at 95uC for either 0,
5, or 10 minutes to generate a distribution of DNA sizes. The
resulting DNA fragments demonstrated modes of 525, 225, and
140 bp. Each aliquot was labeled separately and paired in four
combinations to create both size-matched and mismatched
fragment pairs (matched pair: 225/225 and mismatched pairs:
525/225, 525/140, 225/140). These paired samples were then
hybridized to Agilent 180 K feature arrays to model the variation
in DNA fragment size commonly present in test and reference
samples competitively hybridized to arrays.
Despite the initially intact and identical condition of the gDNA
in each pair, three out of four self-hybridizations failed to achieve
derivative log ratio spread (dLRsd) values less than 0.3, a
primary QC metric and threshold for array data quality [19,28]
(Figure 1). The self-hybridization pair with matched DNA size
distributions that had been exposed to identical fragmentation
conditions resulted in a dLRsd of less than 0.3 (Figure 1A, B),
indicating a hybridization likely to yield robust copy number
data. The introduction of even moderate size mismatches
(300 bp differential) was sufficient to introduce profound changes
in final data quality, even when the mismatch resulted from an
increase in fragment size (Figure 1C, D). Additional loss of data
quality was noted when the difference in fragment sizes between
the competitively hybridized DNA samples was further increased
to 385 bp (Figure 1E, F). The magnitude of the size mismatch
effect on data quality is not completely dependent on the
magnitude of the size differential, however; as seen in the high
dLRsd of the array data in Figure 1G, H, it is likely that
decreased fragment size also adds complexity to the mechanism.
These findings demonstrate that fragment size matching is
critical for reducing the variability of array data quality even
when using highly intact, optimal DNA samples.
Determination of Optimal Mode Fragment Size in Size-
matched Samples
Prior studies have indicated that experimental samples with
fragment size distributions less than 300 bp may be a source of
inconsistent aCGH performance [9,16,19,24]. Given that match-
ing fragment and reference DNA sizes improves results and might
alter baseline performance, we sought to re-evaluate what the
optimal fragment size might be under size-matched conditions. To
test this we performed additional self-hybridizations using the
reference gDNA sample and generated a spectrum of size
distributions by varying heat fragmentation times. In total, 16
size-matched self-hybridizations representing seven unique size
distributions (range < 200–700 bp; mode fragment lengths < 225,
250, 315, 400, 525, 625, and 680 bp), were measured in duplicate
(n=5) or triplicate (n=2). In contrast to the size mismatched pairs
shown in Figure 1C, D, E, F, G, H, all self-hybridizations between
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acceptable range (dLRsd ,0.3), regardless of length of the DNA
fragments (Figure 2). We did however observe a significant
correlation between decreased dLRsd and increased mode
fragment size (r=20.85, p=0.015) (Figure 2) with optimal data
quality achieved at mode fragment sizes greater than 400 bp
(Figure 2I). Overall we observed that optimal aCGH data quality
is produced with DNA fragment distributions of paired samples of
similar sizes and mode fragment size greater than or equal to
400 bp.
Tissue Sample DNA Responses to Heat Fragmentation
Conditions are Intrinsically Variable and must be
Determined Empirically
Utilizing our DNA extraction protocol with over 100 FFPE
brain tumor specimens (block ages ranging from one to 15 years,
all estimated to contain .50% tumor tissue) obtained from six
different institutions, 100% of samples yielded DNA with average
fragment sizes greater than 400 bp. Indeed, for most samples the
fragment sizes were well above this size threshold and in
agreement with general size ranges reported in other studies
([9,19]). Agarose gel electrophoresis of 22 DNA extracts from
FFPE tissue blocks ranging in age from one to 13 years confirmed
Figure 1. ‘‘Matching’’ DNA fragment size distributions are necessary for optimal aCGH data. (A,C,E,G) Agarose gel electrophoresis images
and ImageJ gel intensity analysis plots of reference gDNA (Promega) after heat fragmentation. Mode fragment size is indicated in blue (bp) relative to
DNA ladder. Heat times were adjusted to produce four mode fragment size combinations (225/225, 525/225, 525/140, 225/140). (B,D,F,H) Plot of
results from chromosome 1 following self-hybridization of specific combinations of mode size. Differentially labeled aliquots (cy5/cy3) were coded as
follows: green;log2ratio,-0.3, black;-0.3#log2ratio#0.3, red;log2ratio.0.3. Data quality was assessed by dLRsd on Agilent 180 K arrays.
doi:10.1371/journal.pone.0038881.g001
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38881Figure 2. Determination of optimal size among matched DNA fragment size distributions. (A,C,E,G) Agarose gel electrophoresis of
reference gDNA (Promega) aliquots after various heat fragmentation times shown adjacent to ImageJ gel analysis of same lanes, molecular weight
indicated in bp. Mode fragment size of each smear, as measured with ImageJ, indicated in blue. (B,D,F,H) Agilent 180 K array results of self-
hybridizations using reference gDNA (left) and characterized by matching fragment size distributions (B;250/250, D;315/315, F;400/400, H;525/525).
Log2 ratios for signal intensities of differentially labeled aliquots (cy5/cy3) are plotted for probes corresponding to chromosome 1
(green;log2ratio,20.3, black;-0.3#log2ratio#0.3, red;log2ratio.0.3). Data quality was assessed by dLRsd. (I) Mean dLRsd of duplicate (n=5) or
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size of each smear against block age reveals a statistically
significant relationship (r=20.77, p,0.0001) between advanced
age and decreased fragment size (Figure 3B). Despite this
relationship, our results support the conclusion that the initial
(post-extraction) degradation of FFPE-derived DNA does not
preclude obtaining fragment distributions within the optimal range
(Figure 2), even among DNA samples isolated from archival
specimens over ten years old.
Previous mechanistic studies of DNA thermodegradation
describe significantly different rates of depurination and
subsequent fragmentation in single versus double-stranded
DNA [29,30] and other studies have exposed the commonly
overlooked role of nucleic acid degradation in standard PCR
conditions [24,25]. In light of these studies, we sought to
identify whether the thermodegradation that occurs during
labeling and other standard aCGH steps contributed to the
variability in our aCGH results. Since the ULS Cy5 and Cy3
conjugates affect the electrophoretic mobility of DNA, we
designed a simulated labeling reaction that exactly mimics the
salt, solvent, and temperature conditions of the ULS labeling
reaction. We then assessed DNA samples by gel electrophoresis
following these simulated labeling conditions. Measured as the
change in mode fragment size following heat fragmentation
and/or labeling conditions, we observed significantly variable
rates of thermodegradation across samples (Figure 3C, D, E, F),
despite reproducibility in any given sample. Additionally,
variable thermodegradation rates were observed even among
samples of apparently similar initial size distribution, which
confounded attempts to reliably predict the ultimate fragment
size distribution of any given sample after heat fragmentation
and labeling procedures based on the initial fragment size
distribution of that sample. This intrinsic variability in DNA
response to heat conditions in aCGH procedures was seen in all
types of specimens, including fresh, frozen, and FFPE specimens
alike (Figure 3C, D, E, F).
Application of the Fragmentation Simulation Method
(FSM) Allows Reliable Control of DNA Fragmentation
Distributions and Improves Quality of aCGH Results
The variability we observed in DNA thermodegradation rates
suggested that the predefined fragmentation conditions used in
published aCGH-FFPE protocols are unlikely to achieve the size
uniformity required for optimal aCGH results. To increase the
number of samples that yield high-quality aCGH data, we
developed a Fragmentation Simulation Method (FSM) that allows
fragmentation conditions to be tailored to individual samples using
a single, standardized protocol. Observation of the time course of
DNA thermodegradation in both fresh/frozen and FFPE DNA
samples suggested that fragment size decay rates might best be
modeled using an inverse power law as follows:
ft ðÞ ~h1z
h2
tzh3 ðÞ
h4
:
where f(t) is the mode DNA fragment size, in base pairs, of a
sample’s fragment distribution immediately prior to hybridization
(after a variable time of heat fragmentation and a simulated
labeling reaction), t is time of heat fragmentation in minutes, while
h1, h2, h3, and h4 are constant parameters unique for each sample.
We experimentally determined data points (n$4) by exposing
aliquots of a DNA sample ($50 ng each) to variable times of heat
fragmentation (e.g. t=0, 0.5, 1, and 2 minutes), followed by a
simulated labeling reaction. The aliquots were then subjected to
agarose gel electrophoresis and the open source ImageJ analysis
software was used to determine the mode fragment size of each
aliquot’s fragment distribution, f(t) (Figure 4A, D). An iterative
least squares non-linear regression was then used to derive
parameter values (h1, h2, h3, and h4) and fit a curve to the
experimentally observed thermodegradation for each sample.
Once these parameters were determined, the completed model
was used to predict the amount of heat fragmentation time, t,
required to achieve an optimal mode fragment size, f(t), in each
DNA sample (Figure 4B, E). Analysis of test samples subjected to
heat fragmentation for a length of time indicated by the FSM and
subjected to ULS labeling showed that the desired target fragment
sizedistributionwasattained(Figure4C,F).FollowingtheFSMand
ULS labeling, samples are hybridized to arrays without further
modification. Thus FSM provides a single, standardized protocol
that accommodates the unique variation in the fragment size of an
input DNA sample and its inherent thermodegradation rate.
FSM Improves aCGH Quality and Reduces Sample-to-
sample Variability in FFPE Samples
To determine whether the FSM method might improve the
results obtained from both FFPE and non-FFPE tissue samples, we
rigorously compared array data obtained using the FSM protocol
withdataobtainedusingthestandardmanufacturer’sULSprotocol.
HybridizationswereperformedusingAgilentSurePrintstockarrays
with a 1 million feature resolution. A diverse set of FFPE tumor
specimens (n=122), frozen tumor tissues (n=7), primary tumor-
spheres and other tumor cell cultures (n=71) were analyzed (Table
S1). First, we assessed differences in the data quality generated by
FFPE central nervous system (CNS) malignancies obtained from
multiple institutions from blocks of various ages (one to 15 years).
The quality of the array data processed according to the standard
ULS protocol (n=42, mdLRsd=0.36, sdLRsd=0.12) was inferior to
that of samples processed according to the FSM ULS protocol
(n=80, mdLRsd=0.20, sdLRsd=0.03) with the difference reaching
statistical significance (p,0.0001) as assessed by t and F tests
(Figure 5A).
Noting significantly less variance in the quality of the FSM ULS
subset, we chose to test whether the age of the tissue blocks and the
resultant array quality are indeed related to one another, as
previously suggested. In the standard ULS set, the correlation
between increased sample age and lowered dLRsd was strong and
significant (r=0.36, p=0.018), however this was not observed in
the FSM ULS subset (r=0.12, p=0.26) (Figure 5B).
Since an optimal clinical laboratory protocol would ideally be
the same for either fresh or fixed tissues and also because the ULS
direct labeling approach has practical and experimental advan-
tages over the commonly used enzymatic methods [24], we next
examined the utility of the FSM ULS protocol using DNA isolated
from either frozen tissue (n=7) or frozen cells (n=71) and Agilent
1 M feature arrays. As observed in the FFPE sample sets, the
subset of frozen samples processed with the FSM ULS protocol
(n=49, mdLRsd=0.18, sdLRsd=0.04) demonstrated significantly
(p,0.0001) higher quality and less variance than those processed
according to the standard ULS protocol (n=29, mdLRsd=0.34,
triplicate (n=2) size-matched self-hybridizations representing seven fragment size distributions plotted by mode fragment length (225, 250, 315, 400,
525, 625, and 680 bp). Error bars indicate SEM.
doi:10.1371/journal.pone.0038881.g002
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38881Figure 3. DNA fragmentation and thermodegradation are unpredictably variable. (A) Gel electrophoresis image of DNA extracted from 22
FFPE tissue specimens stored in paraffin from one to 13 years. (B) Mode fragment size of samples in (A) plotted by age of paraffin block, linear
regression of data indicated by dashed line. (C) Gel electrophoresis image of DNA from six FFPE specimens intact prior to labeling (i), after ULS
labeling only (0), or after ULS labeling plus 1 min heat fragmentation (1). (D) Mode fragment size of lanes marked 0 and 1 plotted for the six FFPE
samples from the gel shown in (C). (E) Gel electrophoresis image of DNA from three frozen specimens with i, 0, and 1 indicating same conditions as in
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38881sdLRsd=0.15) (Figure 5C). Finally, we compared quality across all
of our FFPE and frozen sample sets as well as a previously
published set of Agilent 244 k array data generated by The Cancer
Genome Atlas project (TCGA) using fresh-frozen glioblastoma
tissue specimens and traditional enzymatic DNA labeling (n=206,
mdLRsd=0.18, sdLRsd=0.05) [31]. One-way ANOVA and Tukey’s
multiple comparison test reveal significant differences between the
standard ULS subsets and each FSM subset as well as the TCGA
subset (p,0.001). As depicted in Figure 5D, no significant
difference was measured, however, between the FSM ULS FFPE
subset, the FSM ULS frozen tissue subset, and the TCGA frozen
tissue subset (p.0.05). Importantly, Figure 5 demonstrates that the
FSM method enables the use of both fresh/frozen and fixed tissue
sources for similarly robust, high-resolution aCGH data.
DNA Fragment Size Matching Facilitated by the FSM
Method is More Critical to Array Quality than Previously
Identified Factors
Having demonstrated the highly significant contributions of
FSM analysis and matched DNA fragment sizes to aCGH quality,
we sought to further assess the relative effects of fragment size
compared to other previously reported variables such as Protein-
ase K digestion time, array hybridization time, and concentration
and source of DNA in array hybridization reactions. DNA from a
single FFPE tumor specimen, GBM1 (characterized by complex
and highly aberrant copy number changes involving single-copy
gains, single-copy losses, and regions of homozygous deletion on
chromosome 13), was processed under multiple conditions and
assayed with Agilent 1 M feature arrays. Comparison of Figure 6A
and 6B supports our previous assertions regarding the significant
improvement of data quality enabled by the FSM. Compared with
data obtained following the FSM ULS protocol (Figure 6A) the
(C), and another samples after ULS labeling conditions plus 2 min heat fragmentation (2). (F) Plot of mode fragment size for lanes marked 0, 1, and 2
plotted for the three frozen samples in (E).
doi:10.1371/journal.pone.0038881.g003
Figure 4. A Fragmentation Simulation Method (FSM) enables accurate prediction and precise control of labeled DNA fragment
sizes. (A–F) Vertical axes indicate DNA bp. (A,D) Gel image of DNA from three FFPE specimens (A) or three frozen specimens (D) either intact, (i), after
ULS labeling conditions only, (0), or ULS labeling conditions and 0.5, 1, 2, 4, 6, or eight minutes heat fragmentation (0.5, 1, 2, 4, 6, 8). (B,E) Utilizing
mode fragment size of lanes in (A) or (D) as data points, FSM regression curves fit to data from each sample. Intersection with target size (dashed line)
reveals FSM prediction for optimal time of heat fragmentation for each sample. (C,F) Agarose gel electrophoresis of samples in (A) or (D) after heat
fragmentation for time predicted by FSM in (B) or (E) and ULS labeling conditions, shown adjacent to ImageJ gel analysis of same lanes. The mode
fragment size of each smear, as measured with ImageJ, is indicated by arrows and solid horizontal lines.
doi:10.1371/journal.pone.0038881.g004
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38881standard ULS protocol yielded a higher dLRsd value (0.44)
(Figure 6B) that precluded accurate detection of copy number
aberrations (Figure S1).
The duration of Proteinase K digestion during DNA extraction
has frequently been identified as playing a critical role in the
liberation of DNA from DNA-protein crosslinks and, consequent-
ly, it is thought to play a role in DNA labeling efficiency,
hybridization, and resulting aCGH quality [8–12,19]. The Agilent
1 M array data shown in Figure 6C was produced from GBM1
DNA exposed to only 15 hours of Proteinase K digestion rather
than the 60 hour digestion in the typical FSM ULS protocol used
for the data in (Figure 6A). The sample was otherwise processed
according to an identical FSM ULS protocol. The effect of the
reduced Proteinase K digestion was measurable by dLRsd
(DdLRsd=0.08), although the data quality (dLRsd=0.23) was well
within recommended QC guidelines (dLRsd#0.30) and aberra-
tions across the whole genome were readily identified visually
(Figure S2) and algorithmically. The chromosome 1 data shown in
Figure 6D, E, F, G, H were generated using a single DNA sample
from FFPE specimen, GBM2, and arrayed using five Agilent 1 M
arrays. The data shown in Figure 6D represents baseline
conditions (FSM ULS protocol, 2 mg each of GBM2 and Promega
reference DNA, 40 hr hybridization). Single conditions were
varied to generate the data shown in Figures 6E, F, G, H.
The tissue requirements of the assay are a critical factor and, as
such, we sought to determine whether the FSM method would
allow input of less DNA and still be able to generate robust results.
The resultant data from Agilent 1 M array hybridizations with
Figure 5. Application of FSM ULS method to FFPE samples creates equivalent results to those from fresh-frozen samples. (A) Plot
showing dLRsd for 122 FFPE tumor specimens processed according to either standard ULS or FSM ULS protocols and analyzed on Agilent 1 M arrays.
(B) Data quality (dLRsd) from (A) plotted by FFPE block age and method. Dashed lines indicate linear regression. Statistics indicate magnitude and
significance of correlation between block age and aCGH data quality. (C) Quality (dLRsd) of Agilent 1 M aCGH data of 78 fresh-frozen tissue
specimens or frozen tumorsphere cell cultures processed according to either standard ULS or FSM ULS protocols. (D) FFPE and Frozen FSM ULS
subsets from (A) and (C) compared to 206 fresh-frozen GBM specimens analyzed on Agilent 244 k arrays from the glioblastoma TCGA study. Statistical
significance was assessed by t test and ANOVA, (****;p,.0001, ns;p.0.05), and error bars indicate mean and standard deviation. Additional QC
metrics data for all samples are provided in Table S2.
doi:10.1371/journal.pone.0038881.g005
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e3888125% and 50% reductions of DNA input (both tissue DNA and
reference DNA) relative to the standard DNA input are shown in
Figure 6E and 6F, respectively (data from additional hybridiza-
tions with 75% and 90% reductions of DNA input provided in
Figure S3, DNA input ranging from 0.2–2.0 ug). While the
expected negative trend is observed in the data quality of these
arrays, it is important to note that even the dLRsd of the array
hybridized with 1 ug DNA input (50% lower than standard) is still
within an acceptable range (0.27). Perhaps more importantly,
detection of copy number alterations by calling algorithms was
100% concordant with that of the baseline data shown in
Figure 6D (concordance was measured as proportion of total
Figure 6. Size matching using FSM is a more critical determinant of array quality than other known variables. (A–H) Probe log2 ratio
(signal intensity test DNA/signal intensity reference DNA) data plotted for a single chromosome (chr.13 or chr.1) from eight Agilent 1 M arrays
(green;log2ratio,-0.3, black;-0.3#log2ratio#0.3, red;log2ratio.0.3). (A–C) Chromosome 13 plotted log2 ratios are representative profiles of three
Agilent 1 M arrays of a single FFPE GBM specimen (GBM1) processed with the FSM ULS protocol (A), standard ULS protocol (B), or FSM ULS protocol
after altered proteinase K digestion during DNA extraction (C) (plotted log2 ratio data for all chromosomes provided in Figure S2). (D–H) Chromosome
1 plotted log2 ratios are representative profiles of five Agilent 1 M arrays of a single FFPE GBM specimen (GBM2) processed using the FSM ULS
protocol, with reduced DNA input in (E) and (F) (see Figure S3 and Figure S4 for detailed copy number analysis). Increased hybridization time (G)
improved quality to a modest degree. Use of FFPE brain tissue as reference DNA (H) did not significantly improve results (dLRsd of 0.21 vs. 0.20 for
standard reference).
doi:10.1371/journal.pone.0038881.g006
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true even on detailed copy number analysis of over 27 tumor
specific aberrations (Figure S3). Examination of probe level
sensitivity and specificity data for single copy gain/loss also
showed highly reliable false positive/negative rates (FPR, FNR
,0.20) at 1 ug of input DNA and reasonable performance even
when only 0.2 ug of DNA was utilized (Figure S4).
Increased duration of hybridization is thought to positively
impact the quality of array data and, because hybridization
beyond 40 hrs may be of practical benefit in many clinical
laboratory settings, we measured the effect of 40% more
hybridization time (56 hrs). Indeed, the lower dLRsd (0.16)
indicated improved quality as expected (Figure 6G), although
detection algorithms did not yield additional information relative
to the baseline data. We conclude that increasing hybridization
times improved data quality and could actually be beneficial when
tissue and DNA quantity are limited but that the magnitude of
such improvement was less than that imparted by fragment size
matching (see Figure 6E, F).
Finally, we sought to determine whether use of reference DNA
of a more closely related tissue type and tissue fixation conditions
might further improve results obtained from experimental
samples. Data obtained from competitive hybridization of an
FFPE brain tumor sample (GBM2 DNA from a glioblastoma) and
genomic DNA isolated from FFPE ‘‘normal’’ brain tissue showed
little suggestion of further improvement in data quality
(dLRsd=0.21).
In summary, the use of FSM to match DNA fragment sizes
(Figure7)unveiledahierarchyoffactorsthataffecttheperformance
of aCGH (Figure 8), and allow focused efforts to improve sample
performance. Consequently, application of FSM expands the range
of samples that can successfullybe analyzed byaCGH.
Discussion
Our results identify some of the major sources of aCGH
variability and provide new methods for improving the data
generated from suboptimal DNA specimens. By using a single
source of high quality reference genomic DNA and carefully
controlling DNA fragmentation, we were able to demonstrate that
mismatched DNA fragment size distributions profoundly alter
competitive hybridization under standard aCGH conditions more
than previously suspected. These data are scientifically supported
by previous biochemical studies which used short, fixed oligonu-
cleotide probes to demonstrate that hybridization efficiency was
inversely proportional to the length of the free (solution-side) end
of the target strand in hybridizations. As a result, hybridization
efficiency is significantly affected by DNA fragment length and the
location of the hybridization along the length of the sequence [32].
When interpreted in the context of competitive hybridization, the
findings of Peytavi et al. suggest that the competition of genomic
DNA fragments may be significantly influenced by size-dependent
hybridization efficiencies. As a fundamental assumption underly-
ing all CGH technology, equivalent hybridization properties of
differentially labeled DNA fragments are necessary if concentra-
tion (i.e. copy number) is to be accurately reflected by signal
intensity at equilibrium [33]. Therefore, we hypothesize that - by
matching the DNA fragment sizes of both samples - we have
presumably minimized differences in hybridization efficiency and
thereby promoted improved data quality.
Additionally, we speculate that matching DNA fragment size
within an optimal size range further increases the proportion of
fragments that are viable hybridization targets and therefore
increases the effective target concentration, driving the hybridiza-
tion towards thermodynamic equilibrium. This effect can explain
the high quality results generated by the FSM ULS method and
why it also allows use of less sample DNA (Figure 6F), similar to
the manner in which extended hybridization improves data quality
(Figure 6G) by allowing the reaction to proceed closer to
equilibrium.
Regardless of mechanism, the empirically demonstrated effect
of matching fragment sizes in competitively hybridized DNA
samples enabled us to apply the FSM ULS protocol and achieve
the robust aCGH data reported here. The utility of FSM ULS
also supports the substantial predictive power of prospective
quality control assays [9,16,23,24]. Since these latter assays based
their sample selection criteria on indirect measures of DNA
fragment size, each enabled a beneficial selection of samples with
more appropriate and homogenous DNA fragment size distri-
butions. We suspect that the percentage of samples that failed to
yield meaningful aCGH data in each study can be explained by
unaccounted DNA fragmentation occurring during labeling, as
well as by variable thermodegradation rates intrinsic to the
sample (Figure 3), and/or dissimilar reference DNA fragment
distributions. DNA fragment size matching is also likely to have
contributed to improved aCGH quality obtained in a recent
study advocating application of DNase I fragmentation and
enzymatic labeling [19]. Notably, this study is among several
recent reports that have also attributed their improved aCGH
performance with FFPE tissues to the labeling of increased
amounts of sample DNA (as much as 5 mg for an Agilent 244 k
array), a practice that has been cited as necessary to overcome
the negative effects of the compromised template DNA [34,35].
While increasing the amount of DNA in the reaction may
achieve similar results, the use of such large amounts of DNA is
not generally practical for application to standard clinical
samples where the amount of tissue available is limited, and
current trends and future technologies will likely necessitate use
of only nanogram amounts of DNA. While our method as
described should allow the widest adoption by labs, we anticipate
that reductions in DNA requirements may be achieved with the
FSM and other methods through use of low-sample volume
capillary gel electrophoresis systems in the size modeling step.
Additional reductions may come from the use of lower resolution
arrays that are generally still of sufficient resolution to identify
the majority of clinically relevant cancer aberrations.
Another likely source of improved results in the methods
described is our preferred use of the chemically based ULS
labeling method over enzymatic methods. Conceptually, ULS
labeling is less affected by fixation-associated artifacts such as
DNA cross-linking and DNA fragmentation. The ULS technol-
ogy, which employs a platinum-based chemical reaction, adds
Cy3 and Cy5 conjugates directly to the sample DNA at the N
7
position of guanine bases, and also is independent of DNA strand
length [12,36]. In contrast, enzymatic labeling further degrades
the DNA during required denaturation steps [25], reduces the
complexity of the original genomic template, and therefore may
introduce bias in downstream copy number data [12]. Yet
despite the advantages of ULS labeling, use of this labeling
approach is not as widely reported, particularly with intact DNA
sources such as fresh tissues or blood [19]. We observed marked
variation in performance of standard ULS labeled samples,
consistent with the outcomes reported by Hostetter et al. As a
result, we believe that application of the FSM method was
integral to the successful hybridization of relatively intact DNA
because the appropriate fragmentation time required by a given
sample was more variable than that of the FFPE derived samples
(Figure 4E). To our knowledge, our study is one of the first large-
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to high-resolution aCGH analysis of non-FFPE as well as FFPE
DNA sources. Our methodology may therefore allow a wider use
of ULS technology, which offers distinct benefits of speed and
simplified sample preparation across cancer and non-cancer
applications (Figure 7).
With regard to the fundamental suitability of FFPE samples
for whole-genome analyses, our results with the FSM ULS
protocol suggest that FFPE DNA is not damaged in any way that
irreversibly affects aCGH performance, but methods to account
for the decreased DNA fragment size encountered must be more
routinely implemented. The correlation between FFPE block age
and increased fragmentation is consistent with the lower success
rates previously reported with older samples when fragment size
was not carefully controlled, but our results suggest that
recommendations that samples older than 10 years of age should
be excluded from research or clinical analysis need to be
reevaluated. Future analysis of samples beyond 15 years of age
may aid in determining whether an upper age limit might exist
for FFPE specimens analyzed by aCGH using FSM or other
methods. Notably, while the Agilent stock 1 M feature array
offers extremely high resolution and a genome wide median
probe spacing of 2.1 kb, the enhanced resolution confers greater
sensitivity to both true copy number alterations as well as ‘‘noise’’
when compared with lower resolution arrays such as the Agilent
244 k array [34,37]. The choice of the Agilent 1 M array for
quality comparisons therefore represents a significantly stringent
standard for any aCGH method and the fact that we achieved
uniform dLRsd below 0.3 over large and diverse samples sets
from multiple international institutions using a wide range of
fixation conditions argues again that the array type and other
variables are potentially minor variables in array performance
relative to sample preparation and hybridization conditions.
In developing the FSM methodology we optimized the
protocol to use commonplace and affordable laboratory equip-
ment and to not require complex procedures. Although this
method uses heat fragmentation, it is likely that other methods
that allow greater control over matched DNA fragment
distributions could also be used successfully. Sample methods
that utilize Covaris, restriction enzyme, or size selection
approaches would be useful to compare to the results from heat
fragmentation reported here. Application of FSM methodology
Figure 7. Overview of proposed methods for FSM ULS processing of FFPE specimens. Summary of methods and timeline for aCGH using
the FSM method. Following DNA extraction, the workflow and protocol for preparation of fresh or frozen samples is identical to FFPE workflow
shown.
doi:10.1371/journal.pone.0038881.g007
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compatible diagnostic laboratory tools can more easily be
implemented into routine clinical use. Perhaps more exciting is
the possibility that the FSM approach of modeling nucleic acid
fragmentation to predict downstream fragment sizes also may
have utility for other hybridization-based reactions, such as
Affymetrix SNP arrays or hybrid capture methods commonly
used in next generation sequencing. While the studies here
should allow clinical applications of aCGH to proceed, future
studies will likely focus on further reducing the complexity,
amount of input DNA, and time required to conduct aCGH
analysis.
Materials and Methods
Tissue and Cell Line Specimens
Formalin-fixed paraffin embedded tissue specimens (n=122)
and fresh-frozen tissue specimens (n=7) were obtained from six
separate institutions under de-identified excess tissue protocols
approved by institutional review boards at each institution (Boston
Children’s Hospital, Boston, MA (CHB); Brigham and Women’s
Hospital, Boston, MA (BWH); Children’s Medical Center of
Dallas, Dallas, TX (CMCD); Johns Hopkins Medical Institute,
Baltimore, MD (JHMI); Children’s National Medical Center,
Washington, D.C. (CNMC); and Marmara University Medical
Center, Istanbul, Turkey (IST)). The IRB/ethics committee of
each institution specifically waived the requirement for consent for
these studies. All FFPE tissue specimens were human CNS
malignancies or ‘‘normal’’ brain controls from non-neoplastic
epilepsy specimens. Tumor samples were estimated to contain
.50% tumor nuclei in all cases. Diagnoses were established by
histologic examination according to the criteria of the World
Health Organization classification by two neuropathologists
(K.L.L. and S.S.). Primary glioma and other brain tumor cell
lines were obtained either from the Dana-Farber Cancer Institute/
Figure 8. Predicted hierarchy of known variables contributing to aCGH data quality.
doi:10.1371/journal.pone.0038881.g008
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(n=64) or from the University of California San Francisco (UCSF)
(n=7).
Reference DNA
Commercial reference genomic DNA (created from fresh
peripheral bloods pooled from five to seven healthy, karyotypically
normal individuals) was purchased from Promega (cat. no.
G1471/G1521, Madison, WI).
DNA Extraction
FFPE tissues. Genomic DNA was extracted from FFPE
tissues using a protocol similar to that previously described [9].
Briefly, 1 mm cores (two to five cores total) or 20 mm sections
(three to five sections total) were taken from regions estimated to
contain greater than 50% tumor cells based on previous pilot
studies showing accurate detection of single copy gains and losses
in samples with .40% tumor nuclei by pathologist estimate of
H&E slides. Cores or sections were placed in sterile nuclease-free
microcentrifuge tubes and paraffin was removed by treating the
tissue in (1.2 ml) xylene. Samples were rinsed twice with 1.2 ml
100% ethanol and allowed to dry at room temperature before the
addition of 0.9 ml 1 M NaSCN and overnight incubation at 37uC.
After 12–24 hrs, samples were rinsed twice in 0.9 ml 1X PBS.
0.34 ml of Buffer ATL (Qiagen, QIAamp DNA FFPE Tissue Kit
cat. no. 56404, Valencia, CA) and 40 ml of Proteinase K (20 mg/
mL) (Qiagen, cat. no. 19131) were added and samples were
incubated in a thermomixer (Eppendorf, cat. no. 022670000,
Hamburg, Germany) set at 56–58uC and 450 rpm. An additional
40 ml Proteinase K was added every 8–12 hrs for a period of 48–
72 hrs. Samples were allowed to cool to room temperature before
the addition of 10–20 ml RNase A (100 mg/mL) (Qiagen, cat.
no. 19101) and a 5–10 minute incubation at room temperature.
After adding 400 ml of Buffer AL (Qiagen QIAamp DNA FFPE
Tissue Kit), samples were placed in thermomixer at 60uC for 10
minutes. 440 ml of 100% ethanol was added and each sample was
split between two QIAamp MinElute Columns (Qiagen QIAamp
DNA FFPE Tissue Kit). Following successive washes with 500 ml
Buffer AW1 (Qiagen QIAamp DNA FFPE Tissue Kit) and 500 ml
80% ethanol, DNA was eluted in 50–100 mlH 2O.
Frozen tissues and cells. Genomic DNA was extracted
from frozen tissue and cell line samples using the DNeasy Blood &
Tissue Kit (Qiagen, cat. no. 69504). The manufacturer’s protocol
was utilized with the inclusion of the optional RNase A treatment
and the replacement of Buffer AW2 with 80% ethanol. DNA was
eluted in 100–200 mlH 2O.
FSM Analysis
Prior to FSM analysis, all DNA samples were concentrated
using 30 K MWCO Amicon Ultra Centrifugal Filter Units
(Millipore, cat. no. UFC503096, Billerica, MA). The use of these
filters also removes ssDNA and dsDNA fragments of 50–60 nt in
length, and facilitates the serial dilution of residual salt and/or
solvent in the purified DNA samples. Concentrated DNA samples
were quantified by absorbance spectroscopy with a NanoDrop
1000 (Thermo Fisher) and diluted to working concentrations
specific to Agilent aCGH array-dependent requirements (e.g.
125 ng/mL for 1 M arrays or 62.5 ng/mL for 180 K arrays).
Briefly, a minimum of 240 ng DNA was removed from each
sample and brought to a total volume of 32 ml with H2O. This
solution was then split into 8 ml aliquots in the same 200 ml PCR
tubes that were to be used for the ULS labeling reactions. These
four aliquots were heat-fragmented at 95uC in a PCR thermo-
cycler for either 0, 0.5, 1, or 2 minutes (FFPE samples) or 0, 2, 4,
or 6 minutes (frozen tissue/cells) immediately followed by a 4uC
cycle of at least 4 minutes duration. Using volume and
composition proportions consistent with the 1 M array ULS
labeling reaction, 2 ml of ULS labeling simulation solution (50%
10X Labeling Solution (Agilent Technologies, Genomic DNA
ULS Labeling Kit cat. no. 5190-0419, Santa Clara, CA), 25%
20 mM NaCl, 25% DMF) was then added to each of the four
aliquots before simulated ULS labeling reaction conditions were
initiated (30 min at 85uC then $10 min at 4uC in PCR
thermocycler). Sample aliquots were combined with 4 ml Orange
(66) Gel Loading Dye (New England Biolabs, cat. no. B7022S,
Ipswich, MA) and loaded on 1.5% agarose 1X TBE gels prior to
electrophoresis at 100–120 V. Gels were stained with GelRed
Nucleic Acid Stain (Phenix Research Products, cat. no. RGB-
4103, Candler, NC). Utilizing open-source ImageJ analysis
software (U. S. National Institutes of Health, Bethesda, MD), the
mode fragment size of each aliquot was approximated by
referencing the maximum intensity of each smear with the bands
of a 100 bp DNA Ladder (New England Biolabs, cat. no.
N3231S). The fragmentation of each sample was modeled using
this data in combination with Equation 1 and JMP 8 analysis
software (SAS Institute Inc., Cary, NC), and an optimal heat
fragmentation time was determined.
Array CGH
FSM ULS. Purified DNA extracts from FFPE tissues, frozen
tissues, and frozen cells were heat fragmented as indicated by FSM
analysis. Subsequently, ULS labeling (Agilent Technologies,
Genomic DNA ULS Labeling Kit cat. no. 5190-0419, Santa
Clara, CA) was performed according to the manufacturer’s
suggested protocol. Briefly, 2 mg DNA from each sample was
combined with 2 mL ULS-Cy5 Reagent (Genomic DNA ULS
Labeling Kit) and 2 mL 10X Labeling Solution (Genomic DNA
ULS Labeling Kit) prior to 30 min at 85uC and $10 min at 4uC
in a PCR thermocycler. An equal mass of either male or female
reference DNA was heat-fragmented according to FSM predic-
tions and then labeled with the ULS-Cy3 Reagent (Genomic DNA
ULS Labeling Kit). Unincorporated dye was removed using
Genomic DNA Purification Modules (Agilent Technologies, cat.
no. 5190-0418). The entire volumes of the Cy5-labeled sample
DNA and the Cy3-labeled reference DNA were combined
together with 37.8 mLH 2O, 50 mL Cot-1 DNA (Invitrogen, cat.
no. 15279-011, Carlsbad, CA), 5.2 mL 100X Blocking Agent
(Agilent Technologies, Oligo aCGH Hybridization Kit cat.
no. 5188-5220), and 260 mL 2X Hi-RPM Hybridization Buffer
(Agilent Technologies, cat. no. 5190-0403) before denaturation
(3 min at 95uC) and pre-hybridization (30 min at 37uC). 130 mL
Agilent-CGHblock (Agilent Technologies, cat. no. 5190-0421) was
added to each hybridization solution before 490 mL of the
combined solution was applied to a gasket slide (Agilent
Technologies, cat. no. G2534-60003). A 161 M SurePrint G3
Human CGH Microarray (Agilent Technologies, cat. no.
G4447A) was paired with each gasket slide in a SureHyb Enabled
Hybridization Chamber (Agilent Technologies, cat. no. G2534A)
and the differentially labeled DNA samples were hybridized (65uC)
to the microarray for 40–72 hrs in a hybridization oven (Agilent
Technologies, cat. no. G2545A). During hybridization the slides
were rotated at 19 rpm.
Standard ULS. DNA extracted from FFPE tissues was not
subjected to additional fragmentation prior to ULS labeling. The
intact DNA extracted from frozen tissues and cells, as well as
reference DNA samples, were heat fragmented for ten minutes as
suggested by the manufacturer’s standard ULS protocol. The
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identical to those of the FSM ULS method.
Self-Hybridizations. Single sample self-hybridizations uti-
lized male reference genomic DNA (Promega, G1471, Madison,
WI). DNA was suspended in nuclease-free H2O using 30 K
MWCO Amicon Ultra Centrifugal Filter Units. 500 ng aliquots
were heat-fragmented (95uC) for varying lengths of time and then
differentially labeled with ULS-Cy3 Reagent and ULS-Cy5
Reagent before hybridization to 46180 K SurePrint G3 Human
CGH Microarrays (Agilent Technologies, cat. no. G4449A), and
according to the manufacturer’s standard ULS protocol.
Microarray washing, scanning, and feature
extraction. Microarrays and gaskets were disassembled at room
temperature in Wash Buffer 1 (Agilent Technologies, cat.
no. 5188-5221) and quickly moved to a second dish containing
Wash Buffer 1 and a stir bar rotating at speed sufficient for gentle
agitation of the liquid’s surface. After 5–30 minutes, slides were
moved to a dish containing Wash Buffer 2 (Agilent Technologies,
cat. no. 5188-5222) and a stir bar and agitated at 37uC for 1
minute. Slides were then washed in anhydrous acetonitrile (Sigma-
Aldrich, cat. no. 271004, St. Louis, MO) for 10–15 sec before
being removed and placed in a slide holder (Agilent Technologies,
cat. no. G2505-60525) with an Ozone-Barrier Slide Cover (Agilent
Technologies, cat. no. G2505-60550). Microarrays were scanned
immediately with a DNA Microarray Scanner (Agilent Technol-
ogies, cat. no. G2505C) at 3 mm resolution. Scanned images were
processed using Agilent Feature Extraction v10.7 and FE Protocol
CGH_107_Sep09. Quality control dLRsd statistics were recorded
as reported in the QC Metrics file generated by the software.
Data Analysis
Copy number analysis was performed using the DNA Analytics
module of Agilent Genomic Workbench 6.5. Log2 ratios were
corrected for a periodic ‘‘wave’’ artifact that correlates with GC
content using the software’s GC correction tool with a GC window
size of 2 kb. The ADM-2 algorithm was used with a threshold of
6.0 to detect significantly aberrant genomic regions and detected
regions were filtered for those spanning more than five probes
(,10 kb) with an average absolute log2 ratio .0.3. Array data has
been published in compliance with MIAME 2.0 guidelines and
deposited in the publicly available ArrayExpress database.
Supporting Information
Figure S1 FSM ULS probe level data demonstrates
greater sensitivity and specificity than Standard ULS
probe level data. Female FFPE tumor DNA from sample
GBM1 hybridized with normal male reference DNA (Promega) on
Agilent 1 M arrays using either the FSM ULS or Standard ULS
protocols. Log2 ratio data from X chromosome (XX/XY) and
chromosome 8 (copy neutral) are compared for each array. A)
Receiver operating characteristic (ROC) curves plot sensitivity and
specificity across a range of log2 ratio thresholds and indicate
aberrant (X chromosome) probe values are more readily
distinguished from non-aberrant (chromosome 8) probe values in
FSM ULS data than in Standard ULS data (AUC indicates area
under respective ROC curve). B,C) Given optimized log2 ratio
thresholds defined by ROC analysis (blue), log2 ratio frequency
distributions are plotted and false positive rate (FPR) and false
negative rate (FNR) are calculated. FPR is defined as proportion of
copy neutral (chr8) probe values incorrectly classified as aberrant
and FNR is defined as proportion of aberrant (Xchr) probe values
incorrectly classified as copy neutral.
(TIF)
Figure S2 Whole genome view of Agilent 1 M array data
for FFPE sample GBM1 prepared by FSM versus
standard ULS methods. Log2 ratios plotted for three Agilent
1 M arrays hybridized using either the FSM ULS protocol (left),
the standard ULS protocol (middle), or the FSM ULS protocol
and DNA extracted with reduced duration Proteinase K digestion
(right) as in Figure 6A–C (green; log2ratio,20.3, black;20.3#-
log2ratio#0.3, red;log2ratio.0.3). FSM methods yield lower noise
across the whole genome compared to standard ULS even with
shorter Proteinase K digestion.
(TIF)
Figure S3 FSM ULS protocol enables robust aberration
detection with as little as 10% of recommended FFPE
DNA input. FFPE sample GBM2 (Figure 6D–H) hybridized to
Agilent 1 M arrays using 100% (2.0 mg), 75% (1.5 mg), 50%
(1.0 mg), 25% (0.5 mg), and 10% (0.2 mg) of the recommended
DNA input. Aberration analysis utilized Agilent Genomic
Workbench 6.5 algorithm ADM-2 (threshold=7.0, probes $7,
minimum average absolute log2 ratio $0.35). A) Whole genome
representation of aberrations detected (colored lines above and
below x-axis) in Agilent 1 M aCGH data produced from varying
DNA inputs. B) Summary of detected aberrations reveals a ,96%
(26/27) concordance between aberrations detected using 10% of
standard DNA input and 100% of standard DNA input, though
disparities in interval breakpoints increase significantly with lower
amounts of input DNA. C) Chromosome 1 log2 ratios plotted for
five Agilent 1 M arrays of FFPE GBM specimen GBM2 processed
using the FSM ULS protocol and decreasing DNA inputs
(green;log2ratio,20.3, black;20.3#log2ratio#0.3, red;log2ra-
tio.0.3). While higher dLRsd indicates poorer quality in the
25% and 10% input arrays, similar aberrations (colored lines
above and below x-axis) detected in the higher DNA input arrays
suggest the utility of limited DNA inputs when detection of very
focal (,100 kb) copy number alterations and precise breakpoints
is not necessary.
(TIF)
Figure S4 Effect of FSM ULS protocol and DNA input on
Agilent 1 M aCGH probe level sensitivity and specificity.
Data generated from FFPE sample GBM2 (Figure 6D–H) and
Agilent 1 M arrays using 100% (2.0 mg), 75% (1.5 mg), 50%
(1.0 mg), 25% (0.5 mg), and 10% (0.2 mg) of the recommended
FFPE DNA input. Agilent Genomic Workbench 6.5 algorithm
ADM-2 (threshold=7.0, probes $7, minimum average absolute
log2 ratio $0.35) utilized to define regions of single copy gain
(0.35# average log2 ratio #0.58), single copy loss (21.0# average
log2 ratio #20.35), and non-aberrant copy neutral regions in
GBM2 FSM extended hybridization data (figure 6G) which were
then used to standardize receiver operating characteristic (ROC)
analysis. A,C) ROC curves plot sensitivity and 1-specificity across
a range of log2 ratio thresholds and demonstrate that probe values
in regions of either single copy gain (A) or single copy loss (C) are
more readily distinguished from probe values in copy neutral
regions with greater DNA input (AUC indicates area under
respective ROC curve). B,D) Given ROC optimized log2 ratio
thresholds (dashed lines) for detecting single copy gain (B) or single
copy loss (D) in data from each DNA input, log2 ratio frequency
distributions are plotted for probes in copy neutral regions and
either regions of single copy gain (B) or single copy loss (D). False
positive rates (FPR) and false negative rates (FNR) are calculated
as follows: FPR is defined as proportion of probe values in copy
neutral regions incorrectly classified as aberrant, FNR is defined as
proportion of probe values in regions of gain or loss incorrectly
classified as copy neutral. While the added information of genomic
Fragmentation Simulation Method Improves FFPE aCGH
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mic aberration detection with similar results across all DNA inputs
(see Figure S3), significantly higher probe level FPR and FNR are
observed at lower DNA inputs and indicate compromised array
level resolution.
(TIF)
Table S1 Summary of samples used in the study.
(XLSX)
Table S2 Additional QC metrics data.
(XLSX)
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